Key result
Low-dose erythropoietin fails to improve 6-month LVEF over placebo in STEMI with low ejection fraction.
Why the study?
Previous clinical studies using high-dose erythropoietin in STEMI patients have not shown cardioprotective effects, and the optimal dose remains unknown.
Does low-dose Erythropoietin improve LVEF at 6 months in patients with ST-Segment Elevation Myocardial Infarction?
RCT (n=198)
Double-blind
Randomized
Yes
Does low-dose Erythropoietin improve LVEF at 6 months in patients with ST-Segment Elevation Myocardial Infarction?
Absolute Event Rate: 5.4% vs 8.1%
p-value: p=0.862
Low-dose erythropoietin does not improve left ventricular ejection fraction at 6 months in patients with STEMI.
Neutral pilot findings leave low-dose EPO's cardioprotective role open; larger RCTs needed to confirm or refute benefit.
No takes yet. Share an insight, caveat, or question.
Minamino et al. (2018) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=198). Erythropoietin vs. Placebo was evaluated on LVEF improvement between the acute (4-7 days) and chronic stages (6 months) (p=0.862). Intravenous administration of low-dose erythropoietin did not significantly improve left ventricular ejection fraction at 6 months compared to placebo in patients with STEMI and low LVEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: